D-0215-2018 Class II Terminated

Recalled by SHISEIDO AMERICA INC. — East Windsor, NJ

FDA drug recall D-0215-2018 was initiated by SHISEIDO AMERICA INC. on Dec 14, 2017 and is designated Class II. Reason for recall: GMP Deviations: manufacturing of API material did not meet GMP and quality requirements. The recall status is terminated (terminated Jun 24, 2021).

Recall details

Product Type
Drugs
Report Date
Jan 24, 2018
Initiation Date
Dec 14, 2017
Termination Date
Jun 24, 2021
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Shiseido Future Solution LX Universal Defense SPF 50+ (octinoxate 4.9%, octocrylebe 3.0%, oxybenzone 1.0% and zinc oxide 15.4%), packaged in a) 2mL, b) 15 mL and c) 50 mL tubes, Shiseido Americas Corporation Dist. New York, NY 10022. NDC 58411-256-60

Reason for recall

GMP Deviations: manufacturing of API material did not meet GMP and quality requirements.

Distribution pattern

Product was distributed nationwide.

Code information

SKU#: a) 8C52541, b) 8B41841, c) 1155840, 1155841, 1155842, 1155851, 0710341, 0710342

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0215-2018
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0215-2018. Report a data issue: hello@regdatalab.com.